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Introduction: Although the detection of BRAF p.V600E muta-
tion by immunohistochemistry was clearly described in mela-
noma, discordant evidences were reported for the detection of
p.V600K and p.V600R mutations. The aim of the study was to
evaluate the eﬃcacy of BRAFp.V600E, p.V600K, and p.V600R
detection by immunohistochemistry in melanoma.
Materials and Methods: Immunohistochemistry with VE1 anti-
body was performed on 18 tissue samples of metastatic mela-
nomas with known BRAF mutational status.
Results: The concordance rate of immunohistochemistry was
100% for p.V600E mutation. In contrast, the 7 p.V600K-mu-
tated melanomas were scored as negative. p.V600K-mutated
melanomas were signiﬁcantly associated with older age, male
sex, and worst clinical outcome.
Conclusions: Immunohistochemistry could eﬃcaciously be
adopted as a ﬁrst step for the detection of BRAFp.V600E mu-
tation in the initial selection of patients with advanced mela-
nomas as candidates for BRAF inhibitors. It should be followed
by molecular techniques in p.V600E-negative melanomas, for
the speciﬁc search of p.V600K and other non-p.V600E BRAF
mutations.
Key Words: BRAFp.V600K mutation, BRAFp.V600E im-
munohistochemical assessment, malignant melanoma,
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About 40% to 60% of malignant melanomas are BRAFmutated.1,2 The most common mutations are
BRAFp.V600E (80%) and BRAFp.V600K (5-30%).3
These mutations result (mainly p.V600E) in an enhanced
BRAF kinase activity and an increased phosphorylation
of downstream targets, particularly MEK. Nowadays, the
evaluation of somatic BRAF mutations is required for
molecular-targeted treatments of metastatic melanoma.
In fact, BRAF inhibitors targeting common p.V600E
mutations have become increasingly popular because of
their high objective response rate and few side eﬀects.
BRAF inhibitors have a clinical activity also in melanoma
patients harboring a non-p.V600E BRAF mutation, par-
ticularly p.V600K and p.V600R.4–6 BRAFp.V600M-D
are quite rare and they were not included in the trials for
BRAF-selective inhibitors.5
The ability to recognize BRAFp.V600E mutation
changes according to the methods used for mutation
testing. At present time, the cobas 4800 BRAFp.V600
Mutation Test, approved by FDA and speciﬁcally created
to detect BRAFp.V600E mutation, is able to detect 70%
of BRAFp.V600K mutations.7
Although the immunohistochemical assessment of
p.V600E mutation was clearly reported in melanoma and
other tumors,8,9 discordant evidences were reported for
p.V600K BRAF mutations.2,10 Diﬀerent authors reported
that none of the non-p.V600E cases, including p.V600K,
stained positive with the antibody8,9; in contrast,
Routhier et al10 and Heinzerling et al11 described 2
p.V600K melanomas with positive VE1 staining.
The aim of this paper was to assess the eﬃcacy of
BRAFp.V600E and p.V600K detection by immuno-
histochemistry in melanoma and the distinctive clinical
features of the most common BRAF mutations.
PATIENTS AND METHODS
We selected 35 patients with BRAF-positive ad-
vanced melanoma, diagnosed at the University of Mod-
ena and Reggio Emilia from January 2010. Among these,
18 patients with known BRAF mutational status (12
males, 6 females) were included (Table 1). The 22 re-
maining tissues could not be IHC tested because of
nonavailability of enough sample or missing informed
consent. We decided to analyze the patients’ data and
include them in the study because of their epidemiological
importance.
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Tumor samples were collected according to the
principles of the Declaration of Helsinki after obtaining
informed consent from each patient. The study was ap-
proved by the institutional review board.
IMMUNOHISTOCHEMISTRY
Eighteen melanomas referred for genotyping assay
at our Molecular Diagnostic Laboratory were retrieved
from the pathology database, all with known BRAF
mutational status: p.V600E (n=6), p.V600K (n=7),
p.V600R (n=1), and WT (n=4).
Immunohistochemistry with anti-BRAF antibody
was performed on 5-mm-thick whole tissue sections of
formalin-ﬁxed, paraﬃn-embedded tissue in a automated
immunostainer (Benchmark XT, Ventana) and primary
antibodies against BRAFp.V600E (clone: VE1, 1:100)
(Spring Bioscience, Pleasanton, CA). All slides were
double-blind reviewed by 2 independent observers
(A.M.C. and M.M.). The VE1 antibody staining was
scored as negative when there was no staining or only
isolated nuclear staining. Positive staining was considered
by diﬀuse and moderate (2+) to strong (3+) cytoplasmic
staining. Staining results were interpreted as negative
when there was no staining (0+), or also slight/faint/
barely perceptible staining or staining of only single cells
(1+).
BRAF MUTATION ANALYSIS
Two pathologists reviewed all H&E-stained slides of
primary melanomas. The tumor area of interest was de-
tected and marked on each specimen. DNA was extracted
using the DNeasy Blood & Tissue Kit (Qiagen, Basel,
Switzerland) and tested for BRAF mutations in 2 diﬀerent
laboratories.
Sanger sequencing analyses was performed on all
samples to determine BRAF mutational status. The PCR
product were checked for the right fragment length, pu-
riﬁed and sequenced as previously described.4 Data were
manually edited with the sequencing analysis software
(Applied Biosystems, Darmstadt, Germany).
RESULTS
Average ages were 59 years for patients with p.V600E
and 66 years for patients with p.V600K (Table 1).
BRAFp.V600K-mutated patients had a worse prognosis
compared with their V600E counterparts (Table 2).
The correlation between immunohistochemistry for
VE1 antibody and BRAF mutational status is shown
in Table 1. V600E-speciﬁc antibody stained 6 p.V600E-
mutated melanomas, but no BRAF wild-type or
p.V600K-mutated melanomas. All p.V600E and wild-
type cases were correctly identiﬁed by the 2 pathologists
and the overall concordance rate between protein ex-
pression and BRAFp.V600E mutations was 100% (6/6).
The single BRAFp.V600R-mutated melanoma had a
strong cytoplasmic staining. The 7 BRAF p.V600K-mu-
tated melanomas were reported as negatively stained with
VE1 by both observers (Table 1).
In all cases, the interobserver agreement was almost
total. Cross reactivity was not observed (Fig. 1).
DISCUSSION
Our study shows that, in contrast to BRAFp.V600E
mutation, BRAFp.V600K is not detected by im-
munohistochemistry with VE1 antibody. Our analysis
conﬁrms the high sensitivity and speciﬁcity of VE1 anti-
body in detecting p.V600E mutation, as seen in recently
published studies.8–10 Although isolated instances of
VE1 reactivity in p.V600K-mutant melanoma have been
reported, our ﬁndings clarify the value of this antibody as
a screening tool for V600E mutations.10,11
Even though our results are based on a small sample
size and further studies are still needed to set appropriate
diagnostic standards, we can still highlight some key
concepts.
Although BRAF inhibitors are eﬃcacious on tu-
mors with p.V600E and p.V600K mutations, the 2 tumor
types shall be considered as distinct entities with slightly
diﬀerent age of onset and clinical behavior.2,3
Regarding the response to treatment, the clinical
trials with vemurafenib/dabrafenib including patients
with p.V600K mutations reported worse outcomes and a
strong trend for shorter overall survival (OS) among
p.V600K melanoma patients compared with those with
BRAFp.V600E mutation.2
Recently published studies demonstrated that pa-
tients with BRAFp.V600K mutation are characterized by
an older age of cancer onset, an increased risk for brain
and lung metastases, and a shorter time from diagnosis to
TABLE 1. Correlation of BRAF Mutation Status With
Monoclonal VE1 Immunostaining Evidences
ID Sex Age (y)
BRAF Mutation
Types
VE1 Staining
Pathologist 1
VE1 Staining
Pathologist 2
1 M 69 V600E 3+ 3+
2 F 51 V600E 3+ 3+
3 M 51 V600E 3+ 3+
4 M 50 V600E 3+ 3+
5 F 67 V600E 3+ 3+
6 M 66 V600E 3+ 3+
7 M 75 V600K 0 0
8 M 48 V600K 0 0
9 M 62 V600K 0 0
10 M 74 V600K 0 0
11 M 69 V600K 0 0
12 F 51 V600K 0 0
13 M 82 V600K 0 0
14 M 61 V600R 2+ 2+
15 F 68 WT 0 0
16 M 68 WT 0 0
17 F 70 WT 0 0
18 F 41 WT 0 0
BRAF mutations were detected as following: 25 V600E (c. 1799 T>A; codon
GTG>GAG); 2 BRAF V600 “E2” (c.1799_1800TG.AA:p. Val600Glu); 7 V600K
(c.1798_1799GT.AA:p.Val600Lys); 1 V600R (c.1798_1799GT.AG:p.Val600Arg).
F indicates female; M, male.
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metastasis and death. Reports of melanoma patients with
BRAFp.V600E and p.V600K mutations recognized sig-
niﬁcant diﬀerences in sex, age, primary melanoma loca-
tion, interval from the time of initial melanoma diagnosis
to diagnosis of stage IV disease, and OS after the diag-
nosis of the stage IV disease. p.V600K mutation was
signiﬁcantly associated with older age, male sex, head and
neck primary melanoma site, higher degree of chronic sun
damage, and short OS from the time of diagnosis of stage
IV disease.3
Our case series conﬁrm that p.V600K-mutated
melanomas arise at an older age (59 vs. 66 y old) and is
predominant in males. In this case, it arises in the head
and neck area. Their biological behavior is more ag-
gressive and with tendency to systemic disease, compared
with their p.V600E counterparts.
Our experience conﬁrms, according to recent liter-
ature on the same topic, the eﬃcacy of VE1 in the rec-
ognition of BRAFp.V600R mutation12 (Table 1, Fig. 1);
although just 1 melanoma belonging to our cohort was
p.V600R mutated, the clear staining positivity led us to
the hypothesis that the protein conformational change is
similar enough to the one induced by p.V600E to be
bound by VE1 antibody. However, the risk of mis-
identifying p.V600R as p.V600E by IHC is of limited
clinical relevance. p.V600R mutation is less common than
the others, but it is the third most common mutation
occurring in 5% to 7% of patients with BRAF-mutant
melanoma and there are evidences that the melanoma
patients carrying this mutation can be successfully treated
with oral BRAF inhibitors.6,12
It is known that it is very useful to screen all patients
with advanced melanoma (unresectable stage III and IV)
and high risk of recurrence (stage IIIb and IIIc) for
BRAFp.V600 mutations other than p.V600E, so that a
higher number of patients might beneﬁt from BRAF se-
lective inhibitors. With this regard, BRAFp.V600K mu-
tation, which is present in about 20% of melanomas,
should be investigated with a speciﬁc antibody at
immunohistochemistry or through direct sequencing. In
contrast to p.V600E and p.V600R, in fact, VE1 antibody
is not able to recognize p.V600K.
To sum up, p.V600K-mutated melanomas seem to
constitute a speciﬁc clinical and pathologic entity, show-
ing diﬀerent features in comparison with their p.V600E
counterparts. This becomes evident if we consider the
diﬀerent sensitivity to VE1 antibody at immuno-
histochemistry, which requires the use of distinct anti-
bodies for detecting p.V600K mutation.
Moreover, we realized that the immunohisto-
chemical screening for BRAF mutations, which is less
expensive and less time consuming than molecular se-
quencing, can be eﬃcaciously used in the preliminary
screening of the great majority of BRAFp.V600E-mutated
melanomas. This preliminary analysis could be then fur-
ther enriched through the use of a speciﬁc antibody for
p.V600K mutation and, eventually, direct sequencing for
other BRAF mutations in case of negative immuno-
histochemical staining.T
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FIGURE 1. Immunohistochemistry with anti-BRAF p.V600E-specific VE1 antibody. p.V600E-mutated case with strong positive
cytoplasmic staining of melanoma cells (A); p.v600E-mutated case with strong positive cytoplasmic staining of melanoma cells
(B); p.V600R-mutated case with positive cytoplasmic staining of melanoma cells (20) (C); p.V600R-mutated case with positive
cytoplasmic staining of melanoma cells (40) (D); p.V600K-mutated case with negative cytoplasmic staining (E); BRAF wild-type
(WT) case with negative cytoplasmic staining (F).
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